Place of an opioid analgesic tapentadol pr in the treatment of osteoarthritis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite treatment, patients with osteoarthritis (OA) may experience chronic pain and remain unsatisfied with the therapy. The article analyzes the reasons for the lack of effectiveness of OA therapy, including the presence of central sensitization in some patients, high and medium pain intensity, as well as the presence of contraindications to non-steroidal anti-inflammatory drugs (NSAIDs), which are considered a first-line treatment for inflammatory pain. The review presents the results of the use of the opioid analgesic tapentadol PR for the treatment of pain in OA, its high efficiency compared to NSAIDs and oxycodone is shown. A small number of adverse side effects traditional for opioid analgesics, including low percentage of addiction, have been demonstrated. Good tolerability and high efficacy allow recommending tapentadol PR for elderly patients as a conservative treatment in the presence of contraindications or insufficient efficacy of NSAIDs, in high pain intensity, for postoperative pain therapy, for patients undergoing joint replacement, in the postoperative period and as part of rehabilitation.

Full Text

Restricted Access

About the authors

Ekaterina S. Filatova

V.A. Nasonova Research Institute of Rheumatology

Email: es-filatova@mail.ru

References

  1. Roy S., Meachim G. Chondrocyte ultrastructure in adult human articular cartilage. Ann Rheum Dis. 1968;27:544-58.
  2. Breivik H., Collett B., Ventafridda V., et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J. Pain. 2006;10:287-333. Doi. 10.1016/j.ejpain.2005.06.009.
  3. Kidd B.L. Osteoarthritis and joint pain. Pain 2006;123(1-2):9. Doi: 10.1016/j. pain.2002.00.004.
  4. Wylde V., Hewlett S., iearmonth I.D., Dieppe P. Persistant pain after joint replacement: Prevalence, sensory qualities, and postoperative determinants. Pain. 2011;152:566-72. Doi: 10.1016/j. pain.20W.11.023.
  5. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И. Исследование эффективности прегабалина в терапии хронической боли у пациентов с остеоартрозом коленных суставов. Терапевтический архив. 2017;89(12):81-5. Doi: 10.17116/ terarkh2017891281-85. doi: 10.17116/terarkh2017891281-85.
  6. Staud R., Craggs J.G., Robinson M.E., et al. Brain activity related to temporal summation of C-fiber evoked pain. Pain. 2007;129:130-42.
  7. Woolf C.J. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011;152:S2-S15. Doi: 10.1016/j. pain.2010.09.030.
  8. Woolf C.J. Evidence for a central component of post-injury pain hypersensitivity Nature. 1983;306:686-88.
  9. Waxman S.G., Cummins T.R., Dib-Hajj S., et al. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. Muscle Nerve. 1999;22:1177-87.
  10. Dickenson A.H., Sullivan A.F. Evidence for the role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurons following Cfibre stimulation. Neuropharmacology. 1987;26:1235-38.
  11. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М.: Боргес, 2007. 198 c.
  12. Алексеев В.В., Амелин А.В., Давыдов О.С. и др. Методические рекомендации по диагностики и лечению невропатической боли -Невропатическая боль: клинические наблюдения. Под ред. Н.Н. Яхно и соавт. М.: Издательство РАМН, 2009. C. 6-31.
  13. Clauw D.J. Fibromyalgia. JAMA. 2014;31 1(15):1547-55. Doi:10.1001/ jama.2014.3266.
  14. Desmeules J.A., Cedraschi C., Rapiti E., et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheumatism. 2003;48:1420-29.
  15. Arendt-Nielsen L., Nie H., Laursen M.B., et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573-81. doi: 10.1016/j.pain.2010.04.003.
  16. Lluch Girbes E., Nijs J., Torres Cueco R., et al. Pain treatment for patients with osteoarthritis and central sensitization. Phys Ther. 2013;93:842-51. doi: 10.2522/ptj.20120253.
  17. Nijs J., Torres-Cueco R., Paul van Wilgen, et al. Applying Modern Pain Neuroscience in Clinical Practice: Criteria for the Classification of Central Sensitization Pain. Pain Physician. 2014; 17:447-57.
  18. Smart K.M., Blake C., Staines A., Doody C. Selfreported pain severity, quality of life, disability, anxiety and depression in patients classified with "nociceptive", "peripheral neuropathic" and "central sensitisation" pain. The discriminant validity of mechanisms-based classifications of low back (±leg) pain. Manual Ther. 2012;17:119-25.
  19. Jull G., Sterling M., Kenardy J., Beller E. Does the presence of sensory hypersensitivity influence outcomes of physical rehabilitation for chronic whiplash? A preliminary RCT. Pain. 2007; 129:28-34.
  20. Coombes B.K., Bisset L., Vicenzino B. Thermal hyperalgesia distinguishes those with severe pain and disability in unilateral lateral epicondylalgia. Clin J. Pain. 2012;28:595-601. Doi: 10.1097/ AJP0b013e31823dd333.
  21. Hochman J.P., Gagliese L., Davis A.M. Neuropathic pain symptoms in a community knee OA cohort. Osteoarthritis and Cartilage. 2011;19:647-54. doi: 10.1016/j.joca.2011.03.007.
  22. Dimitroulas T., Duate R.V., Behura A., et al. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheumatol. 2014;44:145-54. Doi: 10.1016/j. semarthrit.2014.05.011.
  23. Thakur M., Dickenson A.H., Baron R. Osteoarthritic pain: nociceptive or neuropathic? Nat Rev Rheumatol. 2014;10:374-80. Doi: 10.1038/ nrrheum.2014.47.
  24. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И. и др. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-35. doi: 10.14412/19954484-2014-631-35. doi: 10.14412/1995-4484-2014-631-35.
  25. Hochman J.R., French M.R., Bermingham S.L. The nerve of Osteoarthritis Pain. Arthritis Care Res (Hoboken). 2010;62(7):1019-23. doi: 10.1002/acr.20142.
  26. Imamura M., Imamura S.T., Kaziyama H.H.S. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: A controlled Analysis. Arthritis Rheumatism. 2008;59(10):1424-31. doi: 10.1002/art.24120.
  27. Arendt-Nielsen L., Hongling Nie, Laursen M.B. Sensitisation in patient with knee osteoarthritis. Pain. 2010;149: 573-81. Doi: 10.1016/j. pain.2010.04.003.
  28. Schroder W., Tzchentke T., Terlinden R., et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. JPET. 2011;337:312-20. Doi: 10.1124/ jpet.110.175042.
  29. Li J.G., Chen C., Yin J., et al. ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci. 1999;65(2):175-85.
  30. Tzschentke T., Jahnel U., Kogel B., et. al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009;45:483-96. doi: 10.1358/dot.2009.45.7.1395291.
  31. Schroder W., Tzchentke T., Terlinden R., et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. JPET 2011;337:312-20. Doi: 10.1124/ jpet.110.175042.
  32. Tzschentke T.M., Christoph T., Kogel B., et al. (-)-1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel mu-Opioid Receptor Agonist/ Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties. J. Pharmacol Exp Ther. 2007;323:265-76.
  33. Schroder W., Tzschentke T.M., Terlinden R., et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. JPET 2011;337:312-20. Doi: 10.1124/ jpet.110.175042.
  34. Регистр лекарственных средств России® РЛС®. 2000-2019.
  35. Schwartz S., Etropolski M., Shapiro D.Y., et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151-62. doi: 10.1185/03007995.2010.537589.
  36. Baron R., Martin-Mola E., Muller M., et al. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study Pain Pract. 2015;15(5):455-70. doi: 10.1111/papr.12200.
  37. Afilalo M., Etropolski M., Kuperwasser B., et al. Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee: Results of a Randomized, Double-blind, Placebo- and Active-controlled Phase 3 Study Clin Drug Invest. 2010;30:489-505.
  38. Steigerwald I., Muller M., Kujawa J., et al. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J. Pain Res. 2012;5:121-38. doi: 10.2147/JPR.S30540.
  39. Banerjee M., Mondal S., Sarkar R., et al. Comparative study of efficacy and safety of tapentadol versus etoricoxib in mild to moderate grades of chronic osteorthritis of knee. Indian J. Rheumatol. 2016;11(1):21-5. Doi:10.1016/j. injr.2015.12.001
  40. Serrie A., Lange B., Steup A. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Curr Med Res Opin. 2017;33(8):1423-32. doi: 10.1080/03007995.2017.133518.
  41. Lange B., von Zabern D., Elling C., Dubois C. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr Med Res Opin. 2017;33(8):1413-22. doi: 10.1080/03007995.2017.1335188.
  42. Hartrick C., Van Hove I., Stegmann J.U., et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31(2):260-71. doi: 10.1016/j.clinthera.2009.02.009
  43. Panella L., Caserta A.V., Ballarati R., et al. Control of post-operative pain and rehabilitation compliance of patients undergoing knee replacement. Clinical Practice (Therapy). 2016;13-2.
  44. Dart R.C., Cicero T.J., Surratt H.L., et al. Assessment of the abuse of tapentadol immediate release: the first 24 months. J. Opioid Manag. 2012;8(6):395-402. doi: 10.5055/jom.2012. 0139.
  45. Butler S.F., McNaughton E.C., Black R.A. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med. 2015;16(1):119-30. doi: 10.1111/pme.12524.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies